Literature DB >> 17482244

Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells.

Xin Li1, Xiaoping Qi, Lingyin Zhou, Deborah Catera, Neal S Rote, Judith Potashkin, Fadi W Abdul-Karim, George I Gorodeski.   

Abstract

OBJECTIVES: To understand the potential role of P2X(7) as biomarker of endometrial cancer, and the molecular mechanisms by which cancerous epithelial cells maintain low expression of P2X(7).
METHODS: Feasibility clinical experimental study. Normal (28), simple or complex hyperplasia (7), complex hyperplasia with atypia (6) and cancer endometrial discarded tissues (40) were obtained from a total of 81 women, ages 25-75. Endpoint for P2X(7) protein was average pixel signal density of tissue immunoreactivity with anti-P2X(7) antibody. Endpoint for P2X(7) mRNA was one-step quantitative Real-Time PCR. Experiments in-vitro included normal (hEVEC) and cancerous cervical epithelial cells (HeLa) transfected with reporter plasmid containing luciferase-3' untranslated region (3'UTR)-P2X(7) cDNA, using as endpoint steady-state luciferase mRNA levels.
RESULTS: Levels of P2X(7) protein and mRNA were significantly lower in vivo, in tissues of complex hyperplasia with atypia or endometrial adenocarcinoma, than in tissues of normal endometrium, simple hyperplasia or complex hyperplasia tissues (sensitivity and specificity of 89-100%, p<0.0001-0.01). Steady-state levels of luciferase mRNA increased over a 6 h incubation period in hEVEC cells transfected with the 3'UTR-P2X(7)-luciferase vector, but decreased in HeLa cells transfected with the reporter plasmid.
CONCLUSIONS: Tissue levels of P2X(7) protein and mRNA can differentiate effectively and accurately between normal and benign hyperplastic endometrial tissues from pre-cancerous and cancer tissues. Cancerous epithelial cells degrade P2X(7) mRNA by activation of instability domains located at the 3'UTR of the P2X(7).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482244      PMCID: PMC2398694          DOI: 10.1016/j.ygyno.2007.03.032

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  23 in total

1.  Glycaemic index, glycaemic load and risk of endometrial cancer: a prospective cohort study.

Authors:  Stephanie A N Silvera; Thomas E Rohan; Meera Jain; Paul D Terry; Geoffrey R Howe; Anthony B Miller
Journal:  Public Health Nutr       Date:  2005-10       Impact factor: 4.022

2.  ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer.

Authors: 
Journal:  Obstet Gynecol       Date:  2005-08       Impact factor: 7.661

3.  Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; James Kauderer; Cornelia Liu Trimble; Steven G Silverberg; John P Curtin; Peter C Lim; Donald G Gallup
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

Review 4.  Receptors for purines and pyrimidines.

Authors:  V Ralevic; G Burnstock
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

5.  ATP stimulates GRK-3 phosphorylation and beta-arrestin-2-dependent internalization of P2X7 receptor.

Authors:  Ying-Hong Feng; Liqin Wang; Qifang Wang; Xin Li; Robin Zeng; George I Gorodeski
Journal:  Am J Physiol Cell Physiol       Date:  2005-02-23       Impact factor: 4.249

6.  Endometrial cancer in young, normal-weight women.

Authors:  Kathleen M Schmeler; Pamela T Soliman; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Karen H Lu
Journal:  Gynecol Oncol       Date:  2005-07-26       Impact factor: 5.482

7.  Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Authors:  Cornelia L Trimble; James Kauderer; Richard Zaino; Steven Silverberg; Peter C Lim; James J Burke; David Alberts; John Curtin
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

8.  Pharmacological characterization of ATP- and LPS-induced IL-1beta release in human monocytes.

Authors:  C B Grahames; A D Michel; I P Chessell; P P Humphrey
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

9.  Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells.

Authors:  Qifang Wang; Xin Li; Liqin Wang; Ying-Hong Feng; Robin Zeng; George Gorodeski
Journal:  Endocrinology       Date:  2004-08-19       Impact factor: 4.736

10.  Epidermal growth factor facilitates epinephrine inhibition of P2X7-receptor-mediated pore formation and apoptosis: a novel signaling network.

Authors:  Liqin Wang; Ying-Hong Feng; George I Gorodeski
Journal:  Endocrinology       Date:  2004-09-30       Impact factor: 4.736

View more
  21 in total

Review 1.  Purinergic signalling in the reproductive system in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-23       Impact factor: 3.765

2.  Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors.

Authors:  Maurish Bukhari; Han Deng; Noelle Jones; Zachary Towne; Craig D Woodworth; Damien S K Samways
Journal:  FEBS Lett       Date:  2015-05-01       Impact factor: 4.124

Review 3.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

4.  Activation of the transcription factor FosB/activating protein-1 (AP-1) is a prominent downstream signal of the extracellular nucleotide receptor P2RX7 in monocytic and osteoblastic cells.

Authors:  Monica L Gavala; Lindsay M Hill; Lisa Y Lenertz; Maya R Karta; Paul J Bertics
Journal:  J Biol Chem       Date:  2010-09-02       Impact factor: 5.157

5.  Role of purinergic receptors in hepatobiliary carcinoma in Pakistani population: an approach towards proinflammatory role of P2X4 and P2X7 receptors.

Authors:  Arun Asif; Madiha Khalid; Sobia Manzoor; Hassam Ahmad; Aman Ur Rehman
Journal:  Purinergic Signal       Date:  2019-08-10       Impact factor: 3.765

Review 6.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

7.  Regulation of P2X(7) gene transcription.

Authors:  Lingyin Zhou; Liping Luo; Xiaoping Qi; Xin Li; George I Gorodeski
Journal:  Purinergic Signal       Date:  2009-07-16       Impact factor: 3.765

8.  P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin.

Authors:  Xin Li; Xiaoping Qi; Lingyin Zhou; Wen Fu; Fadi W Abdul-Karim; Gregory Maclennan; George I Gorodeski
Journal:  Purinergic Signal       Date:  2009-04-28       Impact factor: 3.765

9.  MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3'-untranslated region of the gene that decrease steady-state levels of the transcript.

Authors:  Lingyin Zhou; Xiaoping Qi; Judith A Potashkin; Fadi W Abdul-Karim; George I Gorodeski
Journal:  J Biol Chem       Date:  2008-08-05       Impact factor: 5.157

10.  Cell signaling via the P2X(7) nucleotide receptor: linkage to ROS production, gene transcription, and receptor trafficking.

Authors:  Lisa Y Lenertz; Monica L Gavala; Lindsay M Hill; Paul J Bertics
Journal:  Purinergic Signal       Date:  2009-03-05       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.